Fig. 3From: Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV studyProportion of participants with ≥80 % treatment adherence according to cognitive impairment at weeks 12 and 24 (mITT population). p value assessed via Fisher’s exact test. mITT modified intent-to-treatBack to article page